Solve Therapeutics closed a $120 million financing to advance its antibody‑drug conjugate (ADC) portfolio for solid tumors, citing backing from strategic pharma investors including Merck. The company will use proceeds to accelerate preclinical and early clinical testing of ADC candidates and scale CMC efforts for linker and payload technologies it claims improve stability and therapeutic index. Solve’s raise highlights continued investor support for next‑generation ADC platforms that aim to solve payload delivery and off‑tumor toxicity issues. The financing was described by company spokespeople as oversubscribed and earmarked for IND‑enabling studies and early clinical trial starts. The round places Solve among a cohort of ADC startups securing large growth capital to compete on linker chemistry and payload engineering as big pharmas expand external innovation sourcing for oncology payloads and conjugation platforms.